<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00174824</url>
  </required_header>
  <id_info>
    <org_study_id>LTS6036</org_study_id>
    <nct_id>NCT00174824</nct_id>
  </id_info>
  <brief_title>Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients</brief_title>
  <official_title>Evaluation of Diabetic Retinopathy Progression in Subjects With Type 2 Diabetes Mellitus Treated With Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To compare the progression of diabetic retinopathy in type 2 diabetic patients with
      mild-to-moderate diabetic retinopathy treated with insulin glargine vs NPH human insulin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, open-label assignment of type 2 patients who are on a stable antidiabetic regimen
      to treatment with either insulin glargine or BID NPH human insulin, with baseline diabetic
      retinopathy of severity 53/&lt;53 on the ETDRS scale, for 5 years of followup. Outcomes measured
      by seven-field fundus photography at baseline, 1.5, 3,6,and 9 months, and annually.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients with a 3-step or greater progression in the patient</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>level recoded integer ETDRS retinopathy scale</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients who:develop proliferative retinopathy or develop clinically significant macular edema</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the distribution of patients on the patient level recoded integer ETDRS retiopathy scale</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change from baseline in HbA1c and fasting plasma glucose</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the incidence of hypoglycemia</measure>
  </secondary_outcome>
  <enrollment type="Actual">1024</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes mellitus for at least 1 year

          -  treated with oral antidiabetic agents or insulin at stable doses for at least 3 months

          -  HbA1c between 6 and 12% inclusive

          -  baseline retinopathy severity not to exceed 53/&lt;53 on the ETDRS scale

          -  unlikely to require laser surgery or vitrectomy within upcoming year

        Exclusion Criteria:

          -  prior treatment with insulin glargine

          -  treatment with insulin analogs (eg insulin lispro or aspart) in the year prior to
             enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>March 26, 2009</last_update_submitted>
  <last_update_submitted_qc>March 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Diabetic Retinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

